Abstracts tagged "osteoporosis"

Abstract Number: 0356 • ACR Convergence 2025
An Analysis of Osteoporosis Screening in Males 50 and Older with Rheumatic Disease across Stony Brook Medicine Network
Stephen Poos¹, Hoang Nguyen², Samuel Greenberg³, Marcus Lee², Heidi Roppelt¹ and Asha Patnaik², ¹Stony Brook Southampton Hospital, Southampton, NY, ²Stony Brook University Hospital, Stony Brook, NY, ³Renaissance School of Medicine at Stony Brook University, Stony Brook, NY
Background/Purpose: Osteoporosis is under screened in men. The United States Preventive Services Task Force (USPSTF) does not publish guidelines for osteoporosis screening in men. Other…
Abstract Number: 0338 • ACR Convergence 2025
Fractures and Changes in Bone Mineral Density During Two Years of Low Dose Glucocorticoid Treatment for Rheumatoid Arthritis: A Systematic Literature Review and Individual Participant Data Meta-Analysis
Andriko Palmowski¹, Tobias Haugegaard², Ingiäld Hafstörm³, Henning Bliddal⁴, Judith Oldenkott⁵, Siegfried Wassenberg⁶, Ernest Choy⁷, John Kirwan⁸, Robin Christensen⁹, Maarten Boers¹⁰ and FRANK BUTTGEREIT¹¹, ¹Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ²The Parker Institute, Kopenhagen, Denmark, ³Karolinska Institutet, Stockholm, Sweden, ⁴The Parker Institute, Frederiksberg, Denmark, ⁵Charité, Berlin, Germany, ⁶Rheumazentrum Ratingen, Ratingen, Germany, ⁷Division of Infection and Immunity, CREATE Centre, Cardiff University, Cardiff, United Kingdom, ⁸University of Bristol, Bristol, United Kingdom, ⁹Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Hovedstaden, Denmark, ¹⁰Amsterdam UMC, Vrije Universiteit, Amersfoort, Netherlands, ¹¹Charité University Medicine Berlin, Berlin, Berlin, Germany
Background/Purpose: It is unclear to what extent low dose glucocorticoids (GCs) impact bone health in patients with rheumatoid arthritis (RA). RA leads to bone loss…
Abstract Number: 2595 • ACR Convergence 2025
Impact of Different Types of Physical Activity on Bone Health in Patients with Inflammatory Rheumatic Diseases: a Cross-Sectional Analysis from a Prospective Cohort Study
Edgar Wiebe¹, Claire-Felicia Liebich², Dörte Huscher³, Lien Meerkatt⁴, Andriko Palmowski⁵, Sandra Hermann¹, Burkhard Muche⁵, Zhivana Boyadzhieva², Gerhard Krönke⁶, Bernd Wolfarth² and FRANK BUTTGEREIT⁷, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Berlin, Germany, ³Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Berlin, Germany, ⁴Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Berlin, Germany, ⁵Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁶Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Berlin, Germany, ⁷Charité University Medicine Berlin, Berlin, Berlin, Germany
Background/Purpose: Physical exercise helps maintain bone mineral density (BMD), prevent falls, and reduce fracture risk. Strength and weight-bearing exercises are particularly effective. However, individuals with…
Abstract Number: 2110 • ACR Convergence 2025
Effect of Proton-Pump-Inhibitors on Bone Mineral Density and Microarchitecture in Patients with Inflammatory Rheumatic and Musculoskeletal Diseases
Edgar Wiebe¹, Kerstin Rubarth², Zhivana Boyadzhieva³, Sandra Hermann¹, Burkhard Muche⁴, Gerhard Krönke⁵, Andriko Palmowski⁴ and FRANK BUTTGEREIT⁶, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Berlin, Germany, ³Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Berlin, Germany, ⁴Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁵Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Berlin, Germany, ⁶Charité University Medicine Berlin, Berlin, Berlin, Germany
Background/Purpose: Patients with inflammatory rheumatic and musculoskeletal diseases (iRMDs) are at increased risk of osteoporosis and fragility fractures due to systemic inflammation and glucocorticoid (GC)…
Abstract Number: 0355 • ACR Convergence 2025
Changes in scanographic bone mineral density in melanoma patients treated with immunotherapy
Soukayna Baddi¹, Suarez Dimitri¹, Alexis Ruet¹, Theo Van Butsel¹, Damiano Cerasuolo¹, Jean-Matthieu L’Orphelin¹ and Anne-Christine Rat², ¹Caen University Hospital, Caen, France, ²Caen University hospital, UMR ¹⁰⁷⁵ Caen normandy university, Caen, France
Background/Purpose: The use of immune checkpoint inhibitors (ICIs) is becoming increasingly important in the management of melanoma. However, although ICIs are associated with various immune-related…
Abstract Number: 0337 • ACR Convergence 2025
Bridging the Bone Gap: A Quality Improvement Project on Osteoporosis Screening Practices in a Teaching Institution
Aakanksha Pitliya¹, Alexandra Georgiana Boc², Hema Latha Anam², Richard Oletsky², Dipabali Chaudhuri² and Rajesh Thirumaran², ¹Mercy Catholic Medical Center, Darby, PA, Clifton Heights, PA, ²Mercy Catholic Medical Center, Darby, PA
Background/Purpose: Osteoporosis remains underdiagnosed despite clear guidelines. As primary care physicians and trainees are key to preventive care, this quality improvement (QI) project aimed to…
Abstract Number: 2593 • ACR Convergence 2025
Single Switch from Reference Denosumab to TVB-009 in Women with Postmenopausal Osteoporosis: Analysis of the Phase 3, Randomized, Double-Blind, Multinational, Multicenter Study
Karel Pavelka¹, Frank Schneider², Deepak S³, Bracha Timan⁴, Hadas Barkay⁴ and Anton Buchner², ¹Institute of Rheumatology and Department of Rheumatology, ¹st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ²Teva GmbH, Ulm, Germany, ³Teva Pharma India Private Limited, Bangalore, India, ⁴Teva Pharmaceutical Industries Ltd., Netanya, Israel
Background/Purpose: TVB-009 is being developed as a proposed biosimilar candidate to the reference denosumab. Biosimilarity of TVB-009 to US-licensed denosumab (US-denosumab) and EU-approved denosumab was…
Abstract Number: 2109 • ACR Convergence 2025
Comparative Effects of IL-6 inhibition, Methotrexate, and Glucocorticoid Monotherapy on Bone Mineral Density, 3D-DXA femoral structure and Bone Turnover Markers in GCA and PMR
Edgar Wiebe¹, Lien Meerkatt², Andriko Palmowski³, Zhivana Boyadzhieva⁴, Kerstin Rubarth⁵, Sandra Hermann¹, Burkhard Muche³, Gerhard Krönke⁶ and FRANK BUTTGEREIT⁷, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Berlin, Germany, ³Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁴Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Berlin, Germany, ⁵Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Berlin, Germany, ⁶Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Berlin, Germany, ⁷Charité University Medicine Berlin, Berlin, Berlin, Germany
Background/Purpose: Individuals with giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are at increased risk for osteoporosis and fragility fractures due to long-term glucocorticoid (GC)…
Abstract Number: 0353 • ACR Convergence 2025
Incidence of Clinical Fragility Fractures and Mortality in Patients with Rheumatoid Arthritis Treated with Rituximab
Montserrat Roig Kim¹, Carla Marco-Pascual², Martí Aguilar-Coll¹, Javier Narváez³, Joan Miquel Nolla¹ and Carmen Gomez Vaquero⁴, ¹Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, ²Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ³Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Hospital Universitari de Bellvitge, ⁰⁸⁹⁰⁷ L'Hospitalet, Spain
Background/Purpose: Patients with Rheumatoid Arthritis (RA) have an increased risk of osteoporosis and fragility fractures. Bone loss in RA is multifactorial and mainly determined by…
Abstract Number: 0162 • ACR Convergence 2025
Clinical Relevance of Systematic Comorbidity Screening in Autoimmune and Inflammatory Diseases
Martin Michaud, Caroline Arlet, Jean Alain Bournazeau, François de Maupeou, Julie Gaston, Stephanie Mermet, Helene Coulier, Marie Oustalet, Christophe Raspaud, Cédric Maurice, Sophie Recipon, Claire Verplancken, Kim Paricaud and Leonardo Astudillo, Clinique Saint Exupery, TOULOUSE, France
Background/Purpose: Chronic autoimmune and inflammatory diseases are associated with an increased prevalence of various comorbidities, which may impact both prognosis and therapeutic strategies. EULAR recommends…
Abstract Number: 1066 • ACR Convergence 2024
Development of a Pharmacy-Led Intervention to Improve Osteoporosis Screening in VA Community-Based Outpatient Clinics
Krista Topalsky¹, Lee Arphai², Mary Ellen Amos², Amanda Mertz², Christopher Blum³, Timothy Godbey², Lori Leonard², Maya Mattar⁴, Elizabeth Cable² and Robert Wenzell², ¹University Hospitals/ Case Western Reserve University, Shaker Heights, OH, ²Cleveland VA Medical Center, Cleveland, OH, ³Cleveland VA Medical Center, Cleveland, ⁴Louis Stokes VA medical Center, Mayfield Heights, OH
Background/Purpose: Osteoporosis is a major public health concern in the United States, leading to significant morbidity, mortality, and increased economic burden. Fractures are projected to…
Abstract Number: 2126 • ACR Convergence 2024
Analysis of the Evolution of Bone Mineral Density in the Spanish Population: Results of the OsteoSER Study
Carmen Gomez Vaquero¹, Marta Domínguez-Álvaro², Daniel Seoane-Mato³, Pilar Peris⁴, Santos Castañeda⁵, Eduardo Kanterewicz Binstock⁶, Ramon Mazzucchelli⁷, Luis Arboleya⁸, Miguel Bernad⁹, Antonio Alvarez-Cienfuegos¹⁰, Blanca Correa¹¹, Luis-Maria Jimenez-Liñan¹², Carmen Mateo-Pascual¹³, Mª Mercedes Molina del Rio¹⁴, Mercedes Retamal-Ortiz¹⁵, Aida Fatima Lopez-Laguna¹⁶, Ruth Molera-Valero¹⁷, Sara Alvar-Pariente¹⁸, Antonio Pascual¹⁹, Adolfo Arias-Senso²⁰, Nuria Perez-Gutierrez²¹, Soledad Garcia-Frias²², David Bouza-Alvarez²³, Susana Sostres²⁴, Daniel Suarez-Hernandez²⁵, Ana Zamora-Casal²⁶, Cristina Garcia-Ramirez²⁷ and Enrique González-Dávila²⁸, and OsteoSER Project Collaborative Group, ¹Hospital Universitari de Bellvitge, 08907 L'Hospitalet, Catalonia, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³Sociedad Española de Reumatología, Madrid, Madrid, Spain, ⁴Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ⁵Hospital Universitario de la Princesa, Madrid, Spain, ⁶Hospital Universitari de Vic (Consorci Hospitalari de Vic), Barcelona, Spain, ⁷Hospital Universitario Fundacion Alcorcon, Madrid, Spain, ⁸Hospital Universitario Central de Asturias, Oviedo, Spain, ⁹Hospital Universitario La Paz, Madrid, Spain, ¹⁰Conselleria de Sanitat/Hospital de la Vega Baja, Orihuela, Comunidad Valenciana, Spain, ¹¹Clínica Sanz y Correa, A Coruña, Spain, ¹²Hospital Don Benito-Villanueva, Don Benito, Spain, ¹³Centro de Salud Fuencarral, distrito Fuencarral-El Pardo, Madrid, Spain, ¹⁴Centro de Atención Primaria Viladecans Montbaig, Sant Climent de Llobregat, Spain, ¹⁵Centro de Salud Don Benito Oeste, Don Benito, Spain, ¹⁶Centro de Salud El Molar, El Molar, Spain, ¹⁷Centro de Salud Orihuela 1-El Rabaloche, Orihuela, Spain, ¹⁸Centro de Salud Malpica, Malpica, Spain, ¹⁹Centro de salud Ronda-Norte y Ronda-Sur Santa Bárbara, Ronda, Spain, ²⁰Centro de Salud de Santa Amalia, Santa Amalia, Spain, ²¹Centro de Atención Primaria Ramona Via i Pros, El Prat de Llobregat, Spain, ²²Centro de Salud de Cortes de la Frontera, Cortes de la Frontera, Spain, ²³Centro de Salud Elviña Mesoiro, A Coruña, Spain, ²⁴Centro de Atención Primaria Cap 17 de setembre, El Prat de Llobregat, Spain, ²⁵Centro de Salud de Benejuzar, Benezujar, Spain, ²⁶Centro de Salud Os Mallos, A Coruña, Spain, ²⁷Centro de Salud Ronda-Sur Santa Bárbara, Ronda, Spain, ²⁸Departamento de Matemáticas, Estadística e Investigación Operativa, Universidad La Laguna, San Cristobal de La Laguna, Spain
Background/Purpose: The bone mineral density (BMD) reference data for the Spanish population comes from the study Multicentre Research Project on Osteoporosis (MPRO), concluded in 1989.Our…
Abstract Number: 2145 • ACR Convergence 2024
Study of Bone Metabolism in Patients Diagnosed with Osteogenesis Imperfecta.
Daniel Ramos Castro¹, SAMUEL LEAL², Elena Grau García³, JOSE ELOY OLLER RODRIGUEZ⁴, José Ivorra-Cortés⁵, Carmen Riesco Barcena⁶, Anderson Huaylla Quispe⁷, Pablo Muñoz Martínez⁸, Laura Mas Sánchez⁹, Alba Torrat noves¹⁰, Belén Villanueva Mañés¹¹, Iago Alcántara Álvarez¹², Andrés Pérez Hurtado¹, Miguel Simeo Vinaixa¹¹ and Jose A Román-Ivorra¹³, ¹Rheumatology Department. HUP La Fe, Valencia, Spain, ²Hospital La Fe, Valencia, Spain, ³HUP La Fe, Valencia, Spain, ⁴HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE, VALENCIA, Spain, ⁵Hospital Universitario La Fe, PALMA DE MALLORCA, Spain, ⁶Hospital Universitario i Politecnic La Fe (Valencia-Spain), Valéncia, Spain, ⁷Medicina, Valéncia, Spain, ⁸Hospital Universitario y Politècnico La Fe, Sagunto, Spain, ⁹Resident at Hospital Universitari i Politecnic La Fe, Valéncia, Spain, ¹⁰Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Comunidad Valenciana, Spain, ¹¹Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ¹²Hospital Universitari i Politècnic La Fe, Valéncia, Comunidad Valenciana, Spain, ¹³Hospital Universitari i Politècnic la Fe, Valencia, Comunidad Valenciana, Spain
Background/Purpose: Osteogenesis imperfecta (OI) is a hereditary connective tissue disorder (90% autosomal dominant) characterized by a disruption in type 1 collagen or proteins associated with…
Abstract Number: 1084 • ACR Convergence 2024
Osteoporosis and Osteopenia Diagnosed by Dual-Energy X-Ray Absorptiometry Are Not Increased in Patients with Gout
Karla Miller¹, grant Cannon¹, Kyle Register², Nadia Grant² and Naomi Schlesinger², ¹University of Utah and Salt Lake City VA, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT
Background/Purpose: Controversy exists surrounding the association of gout with osteoporosis diagnosis or incident fragility fractures. Dual-Energy X-Ray Absorptiometry (DXA) scan is the gold standard for…
Abstract Number: 2127 • ACR Convergence 2024
Relationship Between Serum Uric Acid and Trabecular Bone Score (TBS) in Healthy Population
Isabella Silvestre Ignarro¹, Gabriela Tieme Ochikubo², Liliam Takayama³, Valeria de falco Caparbo², Camille Pinto Figueiredo², Marcos Rafael Nogueira Cavalcanti¹, Angelita Gomes De Souza¹, Isabela Judith Martins Bensenor¹, Ricardo Fuller¹ and Diogo Domiciano⁴, ¹Bone Metabolism Laboratory, Division of Rheumatology, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, ²Bone Metabolism Laboratory, Division of Rheumatology, Faculdade de Medicina, Universidade de São Paulo, Sao Paulo, Brazil, São Paulo, SP, Brazil, ³Division of Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, São Paulo, SP, Brazil, ⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil
Background/Purpose: Serum uric acid (UA) has been postulated to play a role against bone loss due to antioxidant mechanisms. Some studies have shown association between…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].